Structural features of the quinidine and quinine molecules necessary for binding of drug-induced antibodies to human platelets.
Although most quinidine- and quinine-induced platelet antibodies react only in the presence of the drug that provoked sensitization, some are active with either quinidine or its stereoisomer, quinine; that is, they are "cross-reactive." This suggests that the activity of drug-dependent antibodies is dependent on different structural features of the quinidine or quinine molecules. To investigate this possibility, we studied reactions of 16 quinidine- and quinine-induced antibodies with quinidine, quinine, and analogues of these drugs modified at the quinoline ring (desmethoxy-derivative), the quinuclidine ring (dihydro-derivative), or the asymmetric C(9)-hydroxyl position. It was found that the antibodies could be classified into three groups on the basis of their reactions with platelets in the presence of these compounds. Eight antibodies (group 1) reacted only in the presence of the sensitizing drug or its dihydro- or desmethoxy-derivative. Three antibodies (group 2) differed from those in group 1 only in that their reactions were markedly weakened when the primary desmethoxy-derivative was used. Five antibodies (group 3) reacted in the presence of the sensitizing drug, its stereoisomer, and one or more of the analogues tested, including at least one of the C(9)-derivatives. Antibodies in this group gave stronger reactions with the sensitizing drug than with its stereoisomer. These results provide further evidence for heterogeneity among drug-induced platelet antibodies by demonstrating that noncross-reactive antibodies (groups 1 and 2) are dependent for their activity on a specific configuration at the optically active C(9)-hydroxyl position, and that some of these (group 2) also require the methoxy group for full reactivity. In contrast, cross-reactive antibodies (group 3) appear to be dependent on the quinoline ring common to all the analogues tested but also require a specific configuration at C(9) for full reactivity.
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000276:immunology*; D000915:Antibody Affinity; D001666:Binding Sites, Antibody; D001792:Blood Platelets / Q000276:immunology*; D002860:Chromium Radioisotopes; D003429:Cross Reactions; D005260:Female; D006801:Humans; D007122:Immunoelectrophoresis; D008297:Male; D008875:Middle Aged; D011802:Quinidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000276:immunology*; D011803:Quinine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000276:immunology*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology
D000906:Antibodies; D002860:Chromium Radioisotopes; D011803:Quinine; D011802:Quinidine